Abstract
Abstract
Among mutations in melanoma, BRAF V600 mutations have historically attracted the most attention and research. However, NRAS, GNAQ, c-KIT, NF1, and atypical BRAF mutations, although less common, warrant identification and consideration. Although consensus guidelines for the treatment and management of these other, non–BRAF V600 mutations are unavailable to date, there has been increased interest in evaluating effective treatments in these subgroups. This article explores the incidence, risk factors, and clinical studies involving these other, less frequent mutations in melanoma to provide guidance and considerations regarding appropriate testing and management of melanomas harboring these mutations.
